EQS-News: Epigenomics AG / Key word(s): 9 Month figures/Quarter ResultsEpigenomics AG reports financial results for the first nine months 2022 09.11.2022 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG reports financial results for the first nine months 2022 Berlin (Germany) and San Diego, CA (U.S.A.), November 9, […]
Author: mark
09. November 2022
Epigenomics AG reports financial results for the first nine months 2022
Read more
02. November 2022
Epigenomics AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
Epigenomics AGEpigenomics AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung 02.11.2022 / 09:53 CET/CESTVeröffentlichung einer Stimmrechtsmitteilung übermittelt durch EQS News – ein Service der EQS Group AG.Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Stimmrechtsmitteilung 1. Angaben zum Emittenten Name: Epigenomics AG Straße, Hausnr.: Geneststraße 5 […]
17. October 2022
Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Epigenomics AG / Total Voting Rights Announcement Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 17.10.2022 / 11:01 CET/CEST Total Voting Rights Announcement transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content […]
17. October 2022
Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Epigenomics AG / Total Voting Rights AnnouncementEpigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 17.10.2022 / 11:01 CET/CESTTotal Voting Rights Announcement transmitted by EQS News – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. […]
19. September 2022
Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs
Epigenomics AG / Key word(s): Change in Forecast/ForecastEpigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs 19-Sep-2022 / 10:36 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS – a service of EQS Group […]
19. September 2022
Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test
EQS-News: Epigenomics AG / Key word(s): StudyEpigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test 19.09.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test First subject has been enrolled in the Company’s CRC-DRAW trial Data […]